Health Care·Biotechnology·$5.3B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.42 | N/A | +7.08% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-0.42 | N/A | +7.08% |
| Revenue | N/A | N/A | N/A |
Tone: Cautiously Optimistic
Management expressed satisfaction with the progress made in their clinical pipeline. They emphasized their commitment to advancing key programs despite not providing specific guidance.
We are pleased with our progress in advancing our pipeline.
Our focus remains on delivering value through our clinical programs.
Xenon Pharmaceuticals reported a loss per share that was slightly better than expected, but did not provide revenue figures. The stock reacted negatively, dropping 1.27%, which may reflect investor concerns about the lack of guidance and clarity on future performance. Overall, the company is focused on its clinical advancements but investors may be looking for more concrete updates in the future.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
AIR PRODS & CHEMS IN
May 10, 2021